BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 24607556)

  • 21. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
    Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.
    Li N; Matte-Martone C; Zheng H; Cui W; Venkatesan S; Tan HS; McNiff J; Demetris AJ; Roopenian D; Kaech S; Shlomchik WD
    Blood; 2011 Nov; 118(22):5965-76. PubMed ID: 21917752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
    Chao NJ
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.
    Choi EY; Choi K; Nam G; Kim W; Chung M
    Front Immunol; 2020; 11():1163. PubMed ID: 32587590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.
    Mutis T
    Int J Hematol; 2003 Oct; 78(3):208-12. PubMed ID: 14604278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia.
    Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; van Egmond HM; Willemze R; Falkenburg JH
    Blood; 2005 Dec; 106(12):3955-7. PubMed ID: 16099884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
    Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minor histocompatibility antigen UTY as target for graft-versus-leukemia and graft-versus-haematopoiesis in the canine model.
    Bund D; Buhmann R; Gökmen F; Zorn J; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2013 Jan; 77(1):39-53. PubMed ID: 23126655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.
    Rutten CE; van Luxemburg-Heijs SA; Griffioen M; Marijt EW; Jedema I; Heemskerk MH; Posthuma EF; Willemze R; Falkenburg JH
    Leukemia; 2008 Jul; 22(7):1387-94. PubMed ID: 18418406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minor histocompatibility antigens--targets of graft versus leukemia responses.
    Riddell SR; Murata M; Bryant S; Warren EH
    Int J Hematol; 2002 Aug; 76 Suppl 2():155-61. PubMed ID: 12430918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
    Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
    Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
    van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
    Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
    Korngold R; Leighton C; Mobraaten LE; Berger MA
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.